Resimmune (VG712) / Angimmune, AOP Orphan Pharma, Virogen Biotech - LARVOL DELTA

Moffitt Cancer Center and Virogen Biotechnology Forge Groundbreaking Partnership to Accelerate Oncology and Immunotherapy Innovations (Moffitt Cancer Center) - "Moffitt Cancer Center...and Virogen Biotechnology Inc...announced a groundbreaking strategic partnership today. This collaboration aims to propel the development of Virogen's cutting-edge fusion protein, VG712 (Resimmune), addressing significant unmet needs in oncology and immunotherapy...Under this strategic alliance, Moffitt will offer Virogen priority access to its world-class clinical expertise and state-of-the-art resources. This includes expedited clinical trial activations, enhanced patient screening and seamless data sharing, ensuring that investigational therapies reach patients swiftly and efficiently....Both parties will contribute intellectually to further advancing VG712 as a lymphodepletion agent."

Licensing / partnership • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

LIMITATIONS OF BUSULFAN/FLUDARABINE-BASED PREPARATIVE REGIMEN IN CTLA-4 HAPLOINSUFFICIENCY TO ACHIEVING DISEASE PHENOTYPE CORRECTION (EBMT 2023) - "Correspondingly, P2 immune phenotype showed both CD4 and CD8 activation with an expansion of cTfh and decreased Treg frequency, which suggests ongoing immune dysregulation.Patient #Patient Age at Dx/HSCTCTLA-4 Gene Mutation & AA ChangeFamily Member AffectedClinical FeaturesImmune Modulators for TxImmunoglobulin Prior to HSCTHSCT DateDonor Match, Type, SourcePreparative RegimenSerotherapyCD34 x10^6 cells/kgGVHD PpxNeutrophil/Platelet EngraftmentComplications Post-HSCTGVHD?T Cell Chimerism (Last Visit, Day +)Myeloid Chimerism (Last Visit, Day +)Medications Last Visit?Outcome111 y/13 yc.442c>T (p.Gln 148*)Yes, mother - unaffected, 2 siblings - asymptomatic, though 1 with low level hypogamEnteropathy, Evans syndrome, lymphoproliferation, recurrent sinus infections, atopy/eczemaSteroids, Sirolimus, Budesonide, AbataceptYes11/5/18MSD 10/10, MarrowBusulfanFludarabineAlemtuzumab (0.1 mg/kg Days -7 to -5)6.032 x 10^6CSA, MMF, MiravirocDay +22/37MRSA, CMV, C Diff, MSSA, PE,..."

IO biomarker • Acute Graft versus Host Disease • Atopic Dermatitis • Bone Marrow Transplantation • Dermatology • Graft versus Host Disease • Hematological Disorders • Immune Modulation • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Otorhinolaryngology • Psoriasis • Rheumatology • Sinusitis • CD8 • CTLA4

Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma. (PubMed, Cytotherapy) - "The modifications to the TAC scaffold described herein represent an important step in the evolution of this technology, which tolerates a range of expression levels without impacting therapeutic efficacy."

IO biomarker • Journal • Hematological Disorders • Hematological Malignancies • Immunology • Multiple Myeloma • Oncology

[VIRTUAL] AT1636, a colon cancer survivor-derived antibody recognizes a previously unidentified truncated, O-mannosylated 70kDa variant of E-cadherin. (SITC 2020) - "From a carrier of a pathogenic gene variant in the MSH6 gene diagnosed with stage IV CRC and liver metastasis that had been treated with avastin, capecitabine and oxaliplatin, peripheral-blood memory B cells were obtained 9 years after last treatment. This variant might play a role in tumor-cell invasion and metastasis. More importantly, we provide a rationale to advance AT1636 based therapeutics for treatment of CRC."

Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor • BCL2L1 • BCL6 • CDH1 • MSH6

[VIRTUAL] Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody (SITC 2020) - "It effectively activated T cells and lysed tumor cells both in vitro and in vivo. This approach could in theory be used to target cancers containing mutations that are difficult to target in conventional ways."

IO Biomarker • Tumor-specific neoantigens • Oncology • TP53

[VIRTUAL] Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody (SITC 2020) - "It effectively activated T cells and lysed tumor cells both in vitro and in vivo. This approach could in theory be used to target cancers containing mutations that are difficult to target in conventional ways."

IO Biomarker • Tumor-specific neoantigens • Oncology • TP53

[VIRTUAL] AT1636, a colon cancer survivor-derived antibody recognizes a previously unidentified truncated, O-mannosylated 70kDa variant of E-cadherin. (SITC 2020) - "From a carrier of a pathogenic gene variant in the MSH6 gene diagnosed with stage IV CRC and liver metastasis that had been treated with avastin, capecitabine and oxaliplatin, peripheral-blood memory B cells were obtained 9 years after last treatment. This variant might play a role in tumor-cell invasion and metastasis. More importantly, we provide a rationale to advance AT1636 based therapeutics for treatment of CRC."

Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor • BCL2L1 • BCL6 • CDH1 • MSH6

[VIRTUAL] A colon cancer survivor-derived antibody recognizes a previously unidentified truncated, O-mannosylated 70kDa variant of E-cadherin (AACR-II 2020) - "From a carrier of a pathogenic gene variant in the MSH6 gene diagnosed with stage IV CRC and liver metastasis that had been treated with avastin, capecitabine and oxaliplatin, peripheral-blood memory B cells were obtained 9 years after last treatment. This variant might play a role in tumor-cell invasion and metastasis. More importantly, we provide a rationale to advance AT1636 based therapeutics for treatment of CRC."

Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • BCL2L1 • BCL6 • CDH1 • MSH6

A-dmDT390-bisFv(UCHT1) fusion protein in combination with ionizing radiation for treatment of stage IV melanoma (clinicaltrials.gov) - P1/2, N=42; Sponsor: Angimmune LLC; Not yet recruiting -> Recruiting. 

Enrollment open • Melanoma • Oncology

ADJUSTED ADMINISTRATION OF A T-CELL UTILIZING BISPECIFIC ANTI CD3/GD2 CONSTRUCT AND CH14.18MAB IN RELATION TO IMMUNE RECOVERY AFTER ALLOGENEIC SCT IN PATIENTS WITH RELAPSED NEUROBLASTOMA (EBMT 2019) - "...The tumor antigen specific antibody domain, derived from a fab fragment of GD2 14.18 antibody and the T-cell recruiting antibody domain, derived from single chain variable fragment (scFv fragment) of UCHT-1 (CD3) are linked by modified CH2 domain... NG-CU showed enhanced cytotoxicity compared to CH14.18 even in lower concentrations and E:T ratios. Dependent on the differential recovery of effector cells posttransplant either NK-cell based or T-cell based antibody constructs might result in optimal anti-tumor activity. An adjusted administration of both antibody constructs in relation to the state of immune recovery after SCT could be an alternative to classical approaches."

Clinical